Theravance, Inc.

Theravance Biopharma R&d Ip, LLC

S Derek Turner

Paul Ross Fatheree

Daniel Marquess

Daniel D Long

Adam Aaron Goldblum

Seok-Ki Choi

Martin Sheringham Linsell

Roland Gendron

Daniel G Genov

Lan Jiang

Robert S Chao

James Bradley Aggen

Edmund J Moran

Sean Gary Trapp

Matthew B Nodwell

Jyanwei Liu

Jason P Chinn

The invention provides novel quinolinone-carboxamide 5-HTreceptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HTreceptor activity, and processes and intermediates useful for preparing such compounds.

Quinolinone-carboxamide compounds as 5-HT4 receptor agonists

The invention provides a crystalline hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with 5-HTreceptor activity, and processes useful for preparing such crystalline salt forms.

Crystalline form of a quinolinone-carboxamide compound

[object Object]

The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds of Formula (I). The invention also provides pharmaceutical compositions comprising such compounds, the use such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds. Wherein; Ris hydrogen, halo, hydroxy, Calkyl, or Calkoxy; Ris Calkyl, or Ccycloalkyl; Ris hydrogen or Calkyl: Ris S(O)Ror C(O)R; Ris hydrogen, Calkyl, Calkyl substituted with &#x2014;OH or Calkoxy, or &#x2014;CH-pyrydyl; Ris Calkyl; or Rand Rtaken together from Calkylenyl; and Ris hydrogen, Calkyl, or pyrydyl; or pharmaceutically-acceptable salt or solvate or stereoisomer thereof. 

This invention provides cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.

Cross-linked glycopeptide-cephalosporin antibiotics

The invention provides novel indazole-carboxamide 5-HTreceptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HTreceptor activity, and processes and intermediates useful for preparing such compounds.

Indazole-carboxamide compounds

Growing community of inventors

San Francisco, CA, United States of America

S Derek Turner